None listed
Conditions
Interventions
Group 1: 1. Suitable patients will be included once the detailed explanation has been given and the relevant informed consents have been signed.
2. The clinical record and documentation of the charact
Sponsors
Dekanat der MLU Halle-Wittenberg
Eligibility
Sex/Gender
All
Age
1 Days to 16 Years
Inclusion criteria
Inclusion criteria: Gender: Both, male and female Minimum age: 1 day Maximum age: 16 years Additional Inclusion Criteria 1. Confirmed JIA (according to ILAR 1997) 2. Age = 1 day up to = 16 years for patients with JIA and joint infections 3. Age for autopsy cases (non-JIA): premature babies up to 16 years of age 4. In the case of JIA and “non-synovectomy cases”: New manifestation of JIA and/or prior to use of immunomodulation (corticoids, MTX, other basic medications, biologicals) 5. Collection of a blood sample, puncture of the joint, arthroscopic synovectomies, open synovectomies or chondrectomies for a medical indication (e.g. JIA or joint infection) 6. Infections of joints before antibiotic treatment 7. Authorised autopsies for deceased children and adolescents
Exclusion criteria
Exclusion criteria: 1. Patients with JIA that belong to none or 2 subtypes of JIA 2. Any infection in the autopsy group 3. Any infection in the JIA group 4. Any infection in the synovectomy group 5. Lack of medical indication to collect blood samples, arthrocenteses, synovectomies, chondrectomies or procedures on the joint in general 6. Patients who have already commenced immunosuppression or immunomodulation in the JIA group (non-synovectomies) 7. Procedures on the jaw joint 8. Suspected shaken baby syndrome in the autopsy groups 9. Lack of written consent forms of the parents and/or patients to any medically indicated joint procedures or to collect blood samples 10. Lack of written informed consent forms of the parents/guardians in the cases of clinical post mortem examinations (autopsy cases) 11. Lack of written consent of the public prosecution office in exceptional cases involving court-ordered post mortem examinations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Qualitative and quantitative determination of surface-active substances in the case of JIA in comparison to “healthy” joints and other joint diseases (SP-A to -H) 2. Qualitative and quantitative determination of trefoil factor family peptides TFF 1-3 in various joint diseases 3. Correlation of the evidence of the above-named substances with the age, tissue type or compartment (cartilage, synovial membrane, synovial fluid, blood) as well as the type of joint disease and disease activity | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Deeper understanding and generation of new knowledge with respect to the pathomechanism of joint diseases in children, in particular also the role inherent immunity plays in this 2. Identify possible new targets for anti-rheumatic treatment | — |
Countries
Germany
Contacts
Public ContactThomas Müller
Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin Halle
Outcome results
None listed